secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001171843-25-007179
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias
---------------------------------------------------------------------------

- Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.
- Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.
- Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).
- Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.
- Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/0001171843-25-007179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/f8k_111025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer